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E-mail: g.wagemaker@genetherapy.nlPompe disease is an autosomal recessive lysosomal storage dis-
order characterized by progressive muscle weakness. The dis-
ease is caused by mutations in the acid a-glucosidase (GAA)
gene. Despite the currently available enzyme replacement ther-
apy (ERT), roughly half of the infants with Pompe disease die
before the age of 3 years. Limitations of ERT are immune re-
sponses to the recombinant enzyme, incomplete correction of
the disease phenotype, lifelong administration, and inability
of the enzyme to cross the blood-brain barrier. We previously
reported normalization of glycogen in heart tissue and partial
correction of the skeletal muscle phenotype by ex vivo hemato-
poietic stem cell gene therapy. In the present study, using a
codon-optimized GAA (GAAco), the enzyme levels resulted in
close to normalization of glycogen in heart, muscles, and brain,
and in complete normalization of motor function. A large pro-
portion of microglia in the brain was shown to be GAA posi-
tive. All astrocytes contained the enzyme, which is in line
with mannose-6-phosphate receptor expression and the key
role in glycogen storage and glucose metabolism. The lentiviral
vector insertion site analysis confirmed no preference for inte-
gration near proto-oncogenes. This correction of murine
Pompe disease warrants further development toward a cure
of the human condition.
INTRODUCTION
Pompe disease is an autosomal recessive lysosomal storage disorder
caused by the deficiency of the lysosomal hydrolase acid a-glucosi-
dase (GAA). GAA deficiency hampers the breakdown of glycogen
to glucose and leads to systemic accumulation of glycogen inside
the lysosomes.1–4 The disease manifests as a broad clinical spectrum,
ranging from the most severe and rapidly progressive classic infantile
form to less progressive forms presenting in late adulthood.5 Classic
infantile Pompe disease presents shortly after birth and is character-
ized by profound and progressive skeletal muscle weakness, respira-
tory distress, cardiomyopathy, and death within the first year of life
when untreated.6,7 Patients with classic infantile Pompe disease1014 Molecular Therapy: Methods & Clinical Development Vol. 17 June
This is an open access article under the CC BY-NC-ND license (hthave an overall better survival and improved quality of life when
treated with enzyme replacement therapy (ERT; registered in 2006
as Myozyme, also marketed as Lumizyme), but this therapy has its
limitations. Close to 50% of infants still die at a very young age despite
ERT, and residual disease remains in the other patients due to insuf-
ficient targeting of the skeletal muscles and a neutralizing immune
response, particularly in patients that do not produce any endogenous
acid GAA.8–13 Another limitation of ERT is the inability to cross the
blood-brain barrier. White matter abnormalities and signs of cogni-
tive decline have been reported in long-term survivors of classic in-
fantile Pompe disease treated with ERT. In mice, signs of CNS
involvement and neural deficits have been reported to attribute to res-
piratory dysfunction.14–16
Gene therapy approaches and adjuvant treatments are currently un-
der investigation in preclinical or clinical studies, including the use of
adeno-associated viral vectors,17–19 suppression of autophagy,20 sup-
pression of glycogen biosynthesis,21 the use of chaperones,22,23 and
improved ERTs,24,25 but a single intervention that provides long-2020 ª 2020 The Author(s).
tp://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Recoding the GAA Sequence Increases GAA Enzyme Activity per
Integration, Resulting in Increased GAA Activity in Leukocytes
(A) Gaa/ mice transplanted with 5  105 Lin cells transduced with either the
lentiviral vector expressing the native GAA cDNA (GAA), a codon-optimized GAA
cDNA (GAAco), or GFP (control vector; KO), the transgenes driven by the SF pro-
moter and spleen cells collected 10–12 months after transplantation from n = 3
GAA, n = 5 GAAco, and n = 3 KO mice. GAA activity per vector copy number ± SD.
(B) GAA activity in leukocytes of individual mice 2months after transplantation (GAA,
n = 10; GAAco, n = 10). Significance was calculated by a Mann-Whitney U test (*p <
0.05).
www.moleculartherapy.orglasting therapeutic effect with limited risks to develop immune re-
sponses against the transgene product is still an unmet medical need.
Transplantation of lentiviral vector gene-modified hematopoietic
stem cells (HSCs) has great potential as a delivery tool providingMoleculaa continuous supply of therapeutic enzyme. Successful clinical
trials are currently in progress for X-linked adrenoleukodystro-
phy (X-ALD) and metachromatic leukodystrophy (MLD).26,27
As for Pompe disease, we have previously reported a proof of
principle that gene-modified HSC transplantation ameliorates
the murine Pompe phenotype and results in addition in robust
immune tolerance to the transgene product, which is attributable
to the intrinsic tolerogenic nature of HSC transplantation.28
Although sustained elevated GAA levels were achieved, these
levels were not sufficiently high to effectuate complete depletion
of the accumulated glycogen in skeletal muscle and brain, and to
achieve full correction of locomotor function. In the present pre-
clinical evaluation of gene-modified HSC transplantation we
explored whether a new vector with codon optimization29 of
the GAA sequence would result in improved reversal of the
Pompe disease phenotype.
RESULTS
GAA Enzyme Activities in Blood and Immune Cells
At present, the use of codon-optimized cDNA for improving gene
expression is a generally applied and accepted methodology in the
development of gene therapeutic approaches. In this study, con-
ducted in GAA-deficient knockout (KO) mice, we have explored
a GAAco construct using a multiplicity of infection (MOI) of 20
as a potential vector for lentiviral gene therapy in Pompe disease.
GAAco shares 83% nucleotide sequence identity with the native
cDNA, with 422 of the 940 codons modified. Untreated KO ani-
mals start to manifest symptoms around 6 months of age but their
lifespan is not dramatically shortened.30 After long-term follow up,
i.e., 10–12 months after transplantation, using a study design iden-
tical to that published for the GAA construct to allow for a direct
comparison,28 enzyme activity per vector copy in gene-modified
spleen cells was increased more than 20-fold by the GAAco vector
as compared to the GAA vector (326.42 ± 307.81 versus 14.4 ±
7.7 nmol/h/mg, respectively; Figure 1). Since the percentage of de-
scendants from the transduced stem cells (i.e., chimerism) was
purposely kept at 24.1% ± 5.0% in both groups of mice, the vector
copy numbers, as determined by quantitative PCR, were corrected
for chimerism and were similar in both groups of mice (GAAco,
7.0 ± 2.6; GAA, 7.1 ± 5.3). Since enzyme activity per vector
copy is independent of cell type and chimerism, the level of chime-
rism resulted in an overall 4.4-fold increase in leukocytes, thymus,
and spleen cells.
Glycogen Clearance in Heart Tissue
Gaa/mice present left ventricle hypertrophy and impaired cardiac
function, similar to classic infantile Pompe patients. We previously
reported that transplantation of KO mice with GAA-transduced
HSCs reversed heart remodeling and led to a substantial improve-
ment of cardiac function.28 In the present study we assessed the
GAA activity in heart muscle, the cardiac dimensions, and the heart
rate at 10 months post-transplantation. Treatment with the lentiviral
GAAco vector led to an increase of GAA activity in heart 5-fold higher
than in wild-type (WT) mice (Figure 2A), resulting in near completer Therapy: Methods & Clinical Development Vol. 17 June 2020 1015
Figure 2. Delivery of High Levels of GAA to Cardiac Tissue Clears Glycogen Storage and Normalizes Cardiac Dimension and Rhythm
(A–C) High enzyme levels were detectable in heart tissue (A), resulting in almost complete reduction of glycogen deposition (B) and normalization of the left ventricular mass in
gene therapy-treated mice (C). WT, wild-type animal (n = 3 in biochemical assays, n = 6 in functional tests); GFP, Gaa/ animals treated with GFP control vector (n = 3–4 in
biochemical assays, n = 4–10 in functional tests); GAAco, Gaa/ animals treated with GAAco vector (n = 5). Data are means of 4–6 mice ± SD. Significance was calculated
by a Mann-Whitney U test (*p < 0.05).
Molecular Therapy: Methods & Clinical Developmentnormalization of glycogen (Figure 2B). The cardiac hypertrophy pre-
sent in the untreated Gaa/ mice normalized in the animals that
received HSC-based gene therapy using the GAAco cDNA construct
(Figure 2C). Normalization of the left ventricular (LV) wall thickness
and the LV lumen diameter (data not shown) resulted in a trend to
improvement of the heart rhythm (data not shown) and rate
(Figure 2D).
Glycogen Clearance in Skeletal Muscle and Normalized Motor
Function
Gaa/ mice at 10 months of age have severely impaired skeletal
muscle function. Animals transplanted with GAAco-transduced
HSCs at age 6–8 weeks had high GAA activity in skeletal muscles
when sacrificed 12 months post-transplantation. The muscles
studied included tongue, masseter, quadriceps femoris, gastrocne-
mius, soleus, extensor digitorum longus, and tibialis anterior and
displayed near complete reduction of glycogen (Figure 3A). De-
pending on the particular muscle type, the GAA activity in these
muscles was 3- to 40-fold higher than in WT animals, but due
to the wide spread between the treated animals there was no sig-
nificant difference except for the tongue. However, a clear reduc-
tion of glycogen can be observed. To investigate the effect on mus-
cle function, the mice were subjected to rotarod and voluntary
running wheel tests. Voluntary running wheel activity monitored
for 28 days and starting at 10 months post-transplantation dis-
played no difference between the WT mice and the mice trans-
planted with GAAco-transduced HSCs, whereas GFP-transplanted
mice ran significantly shorter distances per day (Figure 3B). Dis-
secting the number of rotations during the 28 days in bins of
2 min demonstrated that the Gaa/ mice often made fewer rota-
tions than did WT and gene therapy-treated mice (Figure 3C). The
distribution of rotations per 2-min bin was very much the same for
the GAAco-transplanted KO mice and the WT mice, not only in
the lower but also in the higher number of rotations per bin. Fig-1016 Molecular Therapy: Methods & Clinical Development Vol. 17 Juneure S1 shows actograms of three representative mice from each
group, again showing that the GAAco-transplanted and WT
mice outperform the GFP-transplanted mice with regard to daily
running wheel activity. Furthermore, the average speed in the
running wheels during the 28 days was not different between
gene therapy-treated Gaa/ and WT mice, but untreated Gaa/
mice reached an average speed around 2-fold lower (Figure 3D).
Similarly, GAAco-transplanted KO mice managed to stay almost
equally long on the accelerating rotarod as did WT mice (Fig-
ure 3E), whereas untreated mice fell off rapidly.
Glycogen Clearance in Brain Tissue
A few years after ERT became available for patients with Pompe dis-
ease, CNS-related symptoms were revealed. It is well accepted that he-
matopoietic stem cell transplantation (HSCT) can alleviate neurolog-
ical symptoms of lysosomal enzyme deficiencies by contributing to
the pool of enzyme-expressing microglia that resides in the
brain.26,31,32 Transplantation of Gaa/ mice with the GAAco
construct-transduced HSCs led to a significant increase of GAA activ-
ity to a level of approximately half that in brain of WT mice (Fig-
ure 4A), resulting in reduction of glycogen to near normal levels (Fig-
ure 4B), with glycogen staining largely restricted to astrocytes
(Figure 4C).
To display the localization of GAA in detail, we performed immuno-
fluorescence staining of brain sections from mice 3.5 months post-
transplantation, which demonstrated GAA in roughly half of the mi-
croglia and in virtually all astrocytes (Figure 5).
Glycogen Clearance in Visceral Organs and Articular Cartilage
Since glycogen deposition occurs in virtually all tissues, visceral or-
gans were measured for enzyme activity and glycogen content.
High enzyme activity was also detected in these organs (i.e., liver
and kidney), and with full glycogen clearance (Figure 6).2020
Figure 3. GAA Expression Clears Glycogen Storage
and Corrects Skeletal Muscle Function
(A) Near complete reduction of glycogen content in the
skeletal muscles (masseter) (MAS), tongue (TON), soleus
(SOL), quadriceps femoris (QF), gastrocnemius (GAS),
extensor digitorum longus (EDL), and tibialis anterior (TA).
Number of mice per group: WT, n = 3–5; GAAco, n = 4–5;
GFP, n = 3–5. Rotarod and running wheel performance
was determined at 10–12 months post-transplantation
and compared to age-matchedWT and GFP controls. (B)
Distance achieved in a voluntary running wheel. Number
of mice per group: WT, n = 3; GAAco, n = 4; GFP, n = 9.
(C) The number of rotations made in the running wheel
was measured in 2-min bins, categorized in 17 levels of
performance, and the frequency per category was scored
during a period of 28 days. (D) Performance of mice on a
rotarod. Latency indicates the time spent on the rotarod
before falling off. Number of mice per group: WT, n = 6;
GAAco, n = 5; GFP, n = 4. (E) Average speed in the
running wheel. Data are means ± SD and significance
was calculated with a Mann-Whitney U test (*p < 0.05,
**p < 0.01, ***p < 0.001).
www.moleculartherapy.orgCells residing in articular cartilage may be difficult to reach by GAA
due to its impenetrable density and low oxygenation from virtually no
blood supply. Chondrocytes residing in tibio-femoral joint cartilage
of Pompe mice were subjected to periodic acid-Schiff (PAS) staining
(Figure 7). Quantification, with the PAS staining intensity of WT
chondrocytes set at 0%, demonstrated that ~93% of the chondrocytes
were glycogen positive in KO mice, which was reduced to ~45% pos-
itive cells in GAAco-treated animals. In addition to increased PAS
staining intensity, we noted chondrocyte hypertrophy in the articularMolecular Therapy: Methods &cartilage of KO mice, whereas the cartilage of
GAAco-treated mice appeared morphologically
normal compared to age-matched WT mice.
Vector Integration Site Analysis and Safety
Profiling
Bone marrow DNA from five KO mice trans-
planted with GFP-transduced HSCs and 36 KO
mice transplanted with GAAco-transduced
HSCs were used as a template for linear amplifi-
cation-mediated PCR (LAM-PCR) reactions
prior to high-throughput sequencing. A total of
757 unique integration sites were mapped to the
murine genome: 424 in the DNA from mice
transplanted with the GFP vector, and 333 in
theDNAfrommice transplantedwith theGAAco
vector. Hits were widely distributed across the
genome (Figure 8A), and integrationswere anno-
tated to the gene with the nearest transcription
start site. Using this approach, the genes nearest
to each integration site were sorted into 10 bins
based on their expression levels in lineage-nega-
tive (Lin) Sca-1+ c-Kit+ (LSK) bone marrowcells, with genes in the higher expression bins being favored for integra-
tion (Figure 8B).
Integration site genes were screened against a list of 528 oncogenes
compiled by the Retroviral Tagged Cancer Gene Database (RTCGD)
database.33 Fifteen oncogenes were found in the annotation of the
integration sites in GAAco-treated mice (4.2% of the sample pool),
with two oncogenes appearing twice, i.e., Cr2 and Eps15l1. This per-
centage is similar to the frequency of integrations near oncogenesClinical Development Vol. 17 June 2020 1017
Figure 4. Enzyme Activity and Glycogen Levels in
Brain Tissue
(A and B) GAA activity (A) and glycogen content (B) in
whole-brain lysates, 12 months after transplantation.
Data are expressed as mean ± SD. Number of mice per
group: WT, n = 3; GAAco, n = 5; GFP, n = 3. (C) PAS
staining of cerebellum, demonstrating selective storage of
glycogen in astrocytes and residual glycogen in astro-
cytes of gene therapy-treated mice. Significance was
calculated with a Mann-Whitney U test (*p < 0.05).
Molecular Therapy: Methods & Clinical Developmentfound in in vivo studies ofWTmurine Lin cells transduced withGFP
(58 of 1,402, amounting to 4.1%, with oncogene Zfp521 appearing
twice), and close to the frequency expected by random chance (528
oncogenes out of 21,886 RefSeq genes in Ensembl, amounting to
2.5% oncogene frequency in the murine genome). Fifteen genes
were annotated three or more times in the GAAco-treated group
and 25 genes in the GFP-treated group, and these can be considered
common integration sites (CISs) (Tables S1 and S2). Most of the com-
mon integration sites were intronic, and none of the CIS genes was
marked as oncogenes or present in the two highest LSK expression
bins.
DISCUSSION
ERT for Pompe disease is not curative and is only partially effective,
requires weekly or biweekly enzyme infusions, may result in neutral-
izing immune responses to the recombinant enzyme, and is very
expensive. The most severely affected cross-reactive immunologic
material (CRIM)-negative Pompe patients still have a strongly
reduced overall survival, a need for respiratory support, and develop
high antibody titers against the recombinant protein. Hence, a single
intervention with curative intent represents an unmet medical need.
Attempts at gene therapy in Pompe disease include adeno-associated
virus (AAV) through in vivo injections, or using lentiviral vectors, and
ex vivo lentiviral transduction of HSCs.17,19,28,34–37 Although AAV
therapy may correct disease in Pompe mice, and potentially provide
partial reduction of glycogen in brain when secretable GAA fusion
proteins are used, to correct Pompe patients would require a large
AAV vector quantity, which poses a risk of immune responses against1018 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020the transgene product and/or AAV capsid.19 In
a previous report we showed that gene-modified
HSCs provided immune tolerance to GAA, and
that this approach ameliorates the Pompe
phenotype.28 Supranormal enzyme levels were
obtained in hematopoietic cells, and most target
tissues reached enzyme activity similar to that
of WT mice. However, skeletal muscle function
was not fully normalized, and an effect on
glycogen levels in brain tissue was absent. The
present study is based on the hypothesis that
codon optimization of the GAA sequence might
result in enzyme levels sufficient for full correc-tion of the Pompe phenotype. The self-inactivating (SIN) third-gen-
eration lentiviral vector used in this study contained the strong spleen
focus-forming virus (SFFV) viral promoter driving GAAco expres-
sion. Recoding GAA resulted on average in a 20-fold increase of the
acid GAA activity per viral copy number (VCN) in spleen, which
also resulted in increased enzyme activities in target tissues, near com-
plete reduction of glycogen to WT levels, and consequently normal-
ized heart parameters and function in the gene therapy-treated
mice as well as locomotor function in voluntary running wheels
and rotarod tests. The increase of GAA activity in skeletal muscles re-
sulted in a near complete reduction of glycogen shown in Figure 3A,
which ultimately led to a normalization of skeletal muscle function
(Figures 3B–3E).
Despite prominent glycogen storage in brain tissue, Pompe disease, in
contrast to most other lysosomal enzyme deficiencies, does not result
in prominent neurological symptoms. However, some signs of CNS
deficits became apparent in classic infantile patients treated with
ERT.14,38 In addition, neural deficits in Pompe mice may contribute
to respiratory insufficiency39–41 and even skeletal muscle dysfunc-
tion.42 GAA is thought not to pass the blood-brain barrier, so ERT
is not expected to have any effect on glycogen levels in the brain,
but gene therapy approaches may, which require further investiga-
tion. We previously established in the Krabbe mouse model that
monocytes pass the blood-brain barrier to contribute to microglia
and thereby deliver the needed enzyme.43 Based on this rationale,
gene-modified HSCs are used successfully in lentiviral clinical trials
for X-ALD and MLD to counteract the neuronal damage, including
cognitive decline.26,44 Using the GAA lentiviral vector, GAA levels
Figure 5. GAA in Microglia and Astrocytes
(A) Microglia (F4/80, left panel); anti-GAA and Hoechst
staining show that around half of microglia are GAA
positive (arrowheads) and show the presence of GAA-
negative resident microglia (arrows); original magnifica-
tion, 20. (B) Virtually all astrocytes appeared to contain
GAA protein; two representative examples are shown
here. The merged panel of the GFAP and GAA staining
demonstrates the localization of GAA; original magnifi-
cation, 100. Figure S2 shows the reverse magnifica-
tions for microglia and astrocytes, respectively.
www.moleculartherapy.orgwere very low in brain without much effect on glycogen, but using the
vector described in the present study, glycogen levels were reduced
close to WT levels, in accordance with a GAA level approximately
half that of normal mice. As for the mechanism, approximately half
of the microglia appeared to contain GAA and are therefore descen-
dants of transduced stem cells, whereas the resident microglia or the
untransduced donor microglia did not display GAA. This finding is
consistent with a population of resident microglia, which originate
from early yolk sac precursors prior to birth and persist throughout
life, and microglia derived from monocytes infiltrating the brain in
response to tissue damage or inflammation.45–47
Somewhat surprisingly, virtually all astrocytes appeared to contain
GAA. Astrocytes have emerged as major players in energy delivery,
production, utilization, and storage of the brain and almost exclusively
store glycogen, as was also observed in the present study and mostMolecular Therapy: Methods &likely explains the limited neurological symp-
toms in the Pompe disorder in contrast to
most other lysosomal enzyme deficiencies. As-
trocytes play a major role in development, main-
tenance, and modulation of the blood-brain bar-
rier, control energy supply, in particular through
the glucose metabolism and specific neuronal ca-
pacities such as long-term memory, and express
the mannose 6-phosphate receptors by which
GAA is internalized,48–50 which explains why
virtually all astrocytes appeared GAA positive af-
ter treatment by the gene-modified HSC
approach. Such a reduction of the total glycogen
content of the brain should contribute to an
improved overall outcome following gene ther-
apy in classic infantile patients. Interestingly,
the efficacy of our approach was also apparent
in a major reduction in intracellular glycogen
accumulation in articular cartilage despite the
fact that chondrocytes are particularly difficult
to target due to the composition and density of
the surrounding matrix.
The present results were obtained using the
strong gammaretroviral SFFV promoter and arelatively high VCN per cell (an average of 7 VCN per cell) and are
in line with the high doses of ERT required to alleviate the Pompe
phenotype. In a follow-up study we have been able to reduce the
VCN required to 1–2 per cell by glycosylation-independent lysosomal
targeting24,51 (unpublished data).
The initial stem cell gene therapy trials for X-linked severe combined
immune deficiency (SCID) using gammaretroviral gene transfer vec-
tors resulted in successful restoration of T cell immunity, but, unfor-
tunately, in six patients autonomous T cell clones developed into leu-
kemia, among which one patient did not survive. However, it has
meanwhile been recognized that the treated immune deficiency disor-
ders at least co-predispose to leukemia development, given the
absence of leukemia in the adenosine deaminase-deficient (ADA)-
SCID trial,52,53 a 30% incidence in the X-linked SCID trials,54–56
and a 90% incidence in the gammaretroviral Wiskott-Aldrich trial.57Clinical Development Vol. 17 June 2020 1019
Figure 6. Reduction of Glycogen Storage in Visceral Organs
Glycogen values determined in visceral organs at 10–12 months after trans-
plantation of gene-modified cells; data are expressed as mean ± SD. Age-matched
Gaa/ (KO) and wild-type (WT) animals were used as controls; n = 4–10 mice.
Statistical analysis was calculated with a Mann-Whitney U test (*p < 0.05).
Molecular Therapy: Methods & Clinical DevelopmentOf note, no such adverse effects occurredd in any preclinical evalua-
tion or clinical trial of enzyme deficiencies, including ADA-SCID,
which, although listed as a primary immune deficiency, is in essence
a systemic enzyme deficiency. Safety issues of the gammaretroviral
vectors have been improved by third-generation lentiviral vectors
made SIN by deletion of enhancer regions from the long terminal
repeat sequences58–60 to reduce the risk of influencing nearby genes,61
resulting in highly favorable safety profiles, as is also encountered in
the analysis of vector integration sites in Pompe mice, which showed
the expected lentiviral vector integration pattern. A more thorough
comparison of lentiviral vector integration site distributions by vec-
tors containing viral and eukaryotic promoters, various therapeutic
transgenes and used in different species (unpublished data) showed
no significantly increased risk of the strong SFFV promoter in inte-
gration frequency near oncogenes compared to eukaryotic promoters.
Also, genotoxic events were absent during prolonged monitoring of
mice transplanted with stem cells transduced with the GFP or GAAco
vectors.
The present report demonstrates that transplantation of mice at 6–
8 weeks of age with HSCs transduced using a highly efficient over-
night gene transfer method with a third-generation SIN lentiviral vec-
tor containing a codon-optimized transgene driven by the strong
SFFV promoter results in high and sustained GAA activity in the tis-
sues that are most affected in Pompe disease. Consequently, biochem-
ical and functional parameters of heart and skeletal muscle tissues
normalized, and, in addition, glycogen accumulation in the brain ap-
peared to be reduced to near normal levels. Serious adverse effects
were not observed during prolonged monitoring of the treated ani-
mals, resulting in a favorable safety profile confirmed by the integra-
tion analysis. The therapeutic findings warrant further development
including similar, better, and/or safer constructs directed at clinical
implementation of the approach as a single intervention therapy1020 Molecular Therapy: Methods & Clinical Development Vol. 17 Junewith curative intent. Patients with classic infantile and juvenile
Pompe disease are presently seen as the first target group because
of their relative resistance to the negative side effects of bone marrow
transplantation and their upcoming severe pathology when treated
with ERT, whereas late-onset Pompe disease requires further consid-
eration and a specific risk/benefit analysis.
MATERIALS AND METHODS
Animals
Gaa/ mice (FVB/N background) were generated as previously
described.62 Age-matched control female FVB/Nmice (WT) were ob-
tained from Charles River Nederland (Maastricht, the Netherlands)
and used as controls. All procedures for this study were approved
by the Animal Ethics Committee of the Erasmus University Medical
Center, Rotterdam in accordance with legislation in the Netherlands.
Construction of Vector Plasmids
The human GAA native construct driven under the SFFV promoter
has been described previously (pRRL.PPT.SFFV.GAA.bPRE4*.SIN
[GAA]).28 The OptimumGene algorithm and synthesis were per-
formed by GenScript (Piscataway, NJ, USA) to optimize the human
GAA open reading frame for improved expression, including
consensus Kozak sequence and an additional TGA stop codon
(GAAco). GFP in the pRRL.PPT.SFFV.GFP.bPRE4*.SIN vector
(referred to as GFP) was replaced by GAAco, creating the
pRRL.PPT.SFFV.GAAco.bPRE4*.SIN vector (referred to as GAAco).
Transduction and Transplantation of Murine HSCs
Bone marrow was harvested from the femora and tibiae of 8- to 12-
week-old male Gaa/ mice. Lin cells were purified using a mouse
HSC isolation kit (BD Biosciences) and transduced with the GAAco
vector at an MOI of 20 (mice are marked as GAAco) and an MOI
of 2 for the GFP vector, the latter to serve for mock therapy (these
mice are marked as GFP). Cells were transduced overnight in
serum-free enriched Dulbecco’s medium, supplemented with murine
stem cell factor (100 ng/mL), human FMS-like tyrosine kinase 3 mu-
rine ligand (50 ng/mL), and murine thrombopoietin (10 ng/mL), as
previously described.63 Transduced cells (5  105 cells) were trans-
planted via the tail vein of 6- to 8-week-old Gaa/ female recipients
after sublethal irradiation (6 Gy).
Muscle Performance Tests
To determine skeletal muscle function, mice were tested at 12 months
after transplantation on an accelerating rotarod (from 4 to 40 rpm in
5 min; Panlab/Harvard Apparatus Rota Rod, Holliston, MA, USA).
Mice were given two training sessions to adjust to the apparatus, fol-
lowed by three runs with an interval of 5 min, and the average latency
to fall from the rotarod was determined.
The distance run voluntarily in a running wheel was used to measure
activity performance at 10 months after transplantation for 28 days.
Mice were individually housed in type III polyester cages, equipped
with a steel running wheel (diameter 11.8 cm) connected to a sensor
system to detect revolutions of the wheel.64 Running wheel activity2020
Figure 7. Clearance of Glycogen in Articular Cartilage
after Gene Therapy Treatment
PAS staining (dark purple granules) of articular cartilage
shows glycogen storage in approximately 93% of the
chondrocytes of 10-months-old GAA-deficient (GFP) mice.
The GAAco (treated mice (GAAco, bottom panel) show a
reduction in the number of PAS-positive chondrocytes to
approximately 45%, as well as in the intensity of the PAS
staining. Wild-type mice (WT, top panel) have no glycogen
storage detetctable by PAS staining. Original magnification,
40; scale bars represent 100 mm.
www.moleculartherapy.org
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Figure 8. Vector Integration Analysis of Bone
Marrow of Gene Therapy-Treated Mice
(A) Distribution of the retrieved lentiviral integrations on
each chromosome of GAAco-treated mice, 10–
12 months after transplantation. (B) The expression of the
nearest gene to the vector integration site was assigned a
bin from low to high expression. Both integrations ofGFP-
andGAAco-transduced bone marrow are presented. The
vector integrations show the expected lentiviral vector
distribution with more frequent integrations in the higher
expression bins.
Molecular Therapy: Methods & Clinical Development(number of revolutions per 2 min) was continuously recorded using
the ERS program (University of Groningen, Groningen, the
Netherlands). The daily distance that the mice ran was calculated
by multiplying the number of revolutions with the circumference of
the wheels. The average running speed was calculated for the time
that the mice spent in the running wheel.
Tissue Preparation and Histology
At 12months post-transplantation, the mice were fasted overnight and
sacrificed by transcardial perfusion with saline after sedation with ke-
tamine/Sedator mix (Eurovet Animal Health Limited, Bladel, the1022 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020Netherlands). Tissues were collected and ho-
mogenized by TissueLyser II (QIAGEN) twice
for 2.5 min at 30 Hz. Histological assessment
was performed as described earlier.31 PAS (for
glycogen) staining was performed on these slides
as previously described with the exception of
cartilage. The tibialis bones were collected and
undecalcified and embedded in methyl methac-
rylate (MMA). Positive PAS chondrocytes were
counted and displayed as percentages of total
chondrocytes.
Immunofluorescence Staining
For localization of GAA in the brain, trans-
planted mice were overnight fasted and sacri-
ficed by transcardial perfusion with saline fol-
lowed by 4% formaldehyde (FA) in
phosphate-buffered saline (PBS) after adminis-
tration of a ketamine/Sedator mix, 3.5 months
after transplantation (n = 3). The entire brain
was dissected out and overnight fixed in 4%
FA before being frozen in OCT Tissue Tek (Sa-
kura Finetek Europe). Sections were permeabi-
lized in acetone and methanol (1:4 [v/v]) prior
to blocking in 10% fetal calf serum in PBS at
room temperature, and subsequently stained
for GAA (anti-GAA 1:100), anti-glial fibrillary
acidic protein (GFAP; Sigma-Aldrich; 1:500),
and F4/80 (AbD Serotec; 1:200) overnight at
4C. The following secondary antibodies wereused: Alexa Fluor 488/555/647 (Invitrogen; 1:500). Hoechst (Sigma-
Aldrich; 1:15,000) was used for nuclear staining. Tissue sections
were examined by fluorescence microscopy (Leica DMRXA) con-
nected to a Leica DFC 350FX camera.
GAA and Glycogen Assays
GAA activity and glycogen content were determined as described pre-
viously64,65 and corrected for protein content (bicinchoninic acid
[BCA] kit, Pierce). The glycogen content shown in Figures 3 and 7
were obtained using undiluted samples, which may maximally result
in a factor 2 lower compared to the results from titrated samples,
www.moleculartherapy.orghowever irrelevant for the conclusion of correction of glycogen in the
tissues involved.
Quantitative PCR of LV Integrations
Spleen DNA was extracted with the NucleoSpin tissue kit (Bioké). To
determine the vector copies per cell, quantitative PCR was performed
on DNA extracted from spleen cells with HIV-DU3 forward primer
(50-CTGGAAGGGCTAATTCACTC-30) and HIV-PSI reverse
primer (50-GGTTTCCCTTTCGCTTTCAG-30) on the ABI Prism
7900 HT sequence detection system (Applied Biosystems). To deter-
mine the chimerism, Y chromosome-specific Sry locus primers were
used: forward, 50-CATCGGAGGGCTAAAGTGTCAC-30, reverse 50-
TGGCATGTGGGTTCCTGTCC-30. Samples were normalized to
mouse Gapdh (forward primer, 50-CATCACTGCCACCCAGAA
GAC-30, reverse primer, 50-TGACCTTGCCCACAGCCTTG-30).
Samples were analyzed with SDS 2.2.2 software (Applied Biosystems).
LAM-PCR
High-resolution insertion-site analysis by LAM-PCR66 was per-
formed on bone marrow DNA of Gaa/ mice transduced with
SF.GFP (n = 5) or SF.GAAco (n = 36) LV vectors. Restriction
enzyme Tsp509I was used with the lentiviral (HIV) primer set,
and PCR products were run on high-resolution polyacrylamide
(Spreadex) gel. Sequencing reads were analyzed using MAVRIC,67
and to obtain the nearest RefSeq gene, the following settings were
used: no repeat masking; minimum sequence length, 20 bp; mini-
mum BLAST e-value, 0.01; and maximum distance from integration
site to look for genes, 100 kb. Sequences were aligned to the murine
genome via BLAST (v.37) and nearby genes identified using En-
sembl version 59.
Echocardiography
Ten months after transplantation, mice were weighed, anesthetized
with isoflurane, and intubated as previously described.68 Animals
were placed on a heating pad to maintain body temperature at
37C while being artificially ventilated with a mixture of O2 and
N2 (1:2 [v/v]) to which isoflurane (2.5% [v/v]) was added at a
rate of 90 strokes/min using a rodent ventilator (SAR-830/P,
CWE, Ardmore, PA, USA) at an inspiratory pressure of 18 cm
H2O and a positive end expiratory pressure of 4 cm H2O. To de-
hair the chest, Veet hair removal cream (Reckitt Benckiser, Parsip-
pany, NJ, USA) was used. Transthoracic echocardiograms of the
left ventricle were obtained with an Aloka SSD 4000 echo device
(Aloka, Tokyo, Japan) using a 13-MHz probe. Images of the short
and long axes were obtained in two-dimensional and M-mode set-
tings, used to measure the LV lumen diameter and wall thickness
at end diastole and end systole by SigmaScan Pro 5 image analysis
software.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism (GraphPad,
La Jolla, CA, USA). Significance of differences was determined by the
Mann-Whitney U test. A significant difference was assumed at p
<0.05. Error bars represent SD, as indicated in the legends.MoleculaSUPPLEMENTAL INFORMATION
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